Mirae Asset Global ETFs Holdings’s Ligand Pharmaceuticals LGND Stock Holding History

Mirae Asset Global ETFs Holdings’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.92M	Buy	9,250 +173	+2%	+$40.8K	﹤0.01%	1070
2026 Q1	$1.81M	Buy	9,077 +41	+0.5%	+$8.11K	﹤0.01%	1217
2025 Q4	$1.71M	Buy	9,036 +167	+2%	+$32.1K	﹤0.01%	1229
2025 Q3	$1.57M	Sell	8,869 -1,587	-15%	-$236K	﹤0.01%	1252
2025 Q2	$1.19M	Sell	10,456 -204	-2%	-$21.8K	﹤0.01%	1363
2025 Q1	$1.12M	Buy	10,660 +809	+8%	+$91.5K	﹤0.01%	1444
2024 Q4	$1.06M	Buy	9,851 +554	+6%	+$62.6K	﹤0.01%	1515
2024 Q3	$931K	Buy	9,297 +1,162	+14%	+$117K	﹤0.01%	1582
2024 Q2	$685K	Buy	+8,135	New	+$647K	﹤0.01%	1667

Other funds holding LGND

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Mirae Asset Global ETFs Holdings's LGND Position: Q2 2026 in Review

Mirae Asset Global ETFs Holdings increased its Ligand Pharmaceuticals (LGND) stake by 1.9% in Q2 2026, buying an estimated $40.8K and bringing the position to 9,250 shares worth $2.92M. The position accounts for ﹤0.01% of the portfolio, ranked #1070.

Mirae Asset Global ETFs Holdings first reported a position in LGND in Q2 2024 and has held it in 9 quarters since. 417 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

Mirae Asset Global ETFs Holdings held 9,250 shares of Ligand Pharmaceuticals worth $2.92M as of Q2 2026.
Mirae Asset Global ETFs Holdings bought 173 Ligand Pharmaceuticals shares in Q2 2026, an estimated $40.8K.
Ligand Pharmaceuticals made up ﹤0.01% of Mirae Asset Global ETFs Holdings's portfolio in Q2 2026, its #1070 holding.
Mirae Asset Global ETFs Holdings first reported a position in Ligand Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
417 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Mirae Asset Global ETFs Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.